C4 Therapeutics Inc (CCCC) — Cash Flow-to-Debt Ratio
C4 Therapeutics Inc (CCCC) has a Cash Flow-to-Debt Ratio of -0.32x as of March 2026, meaning its operating cash flow of $-29.94 Million could theoretically repay 0% of its total liabilities ($94.61 Million) in one year. Explore how much of C4 Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
C4 Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for C4 Therapeutics Inc across 8 annual periods. Also explore how large is C4 Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for C4 Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for C4 Therapeutics Inc. For market capitalisation and broader financial context, see C4 Therapeutics Inc (CCCC) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.96x | $-98.69 Million | $102.49 Million | ▼ -97.5% |
| 2024 | -0.49x | $-65.16 Million | $133.62 Million | ▲ +40.5% |
| 2023 | -0.82x | $-106.84 Million | $130.34 Million | ▼ -9.6% |
| 2022 | -0.75x | $-105.94 Million | $141.61 Million | ▼ -0.8% |
| 2021 | -0.74x | $-86.97 Million | $117.16 Million | ▼ -31.7% |
| 2020 | -0.56x | $-67.25 Million | $119.35 Million | ▼ -333.3% |
| 2019 | 0.24x | $55.61 Million | $230.22 Million | ▲ +421.8% |
| 2018 | -0.08x | $-16.98 Million | $226.24 Million | — |